GlassScriptPhysician profile
Caroline Howington Hendrix
NPI 1215690540
$5,880.75
in general payments reported to CMS, 2019-2025
19 companies · $781 in 2025
The $781 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $126 · 2023: $2,362 · 2024: $2,406 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,812 · Food and Beverage: $2,609 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,812.48 |
| Food and Beverage | $2,609.49 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,583.52 | 2022-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,803.12 | 2023-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $273.51 | 2021-2025 | |
| Janssen Biotech, INC. | $206.09 | 2023-2025 | Erleada, Akeega, Balversa |
| Calyxo, INC. | $140.02 | 2025 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $114.64 | 2023-2025 | Provenge |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.91 | 2021 | |
| Astellas Pharma US INC | $101.31 | 2024-2025 | Xtandi, Veozah, Myrbetriq |
| Valencia Technologies Corporation | $100.22 | 2024 | Ecoin Device Kit |
| Sumitomo Pharma America, INC. | $98.94 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $90.40 | 2023-2025 | Welireg, Keytruda, Lynparza |
| Abbvie INC. | $53.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.93 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $43.86 | 2025 | Adstiladrin |
| Procept Biorobotics Corporation | $39.77 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.26 | 2024 | |
| Progenics Pharmaceuticals, INC. | $21.58 | 2025 | |
| Sun Pharmaceutical Industries INC. | $14.20 | 2025 | |
| Foundation Medicine, INC. | $13.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.